ArticleJournal of virology2004
Intracellular approach for blocking JC virus gene expression by using RNA interference during viral infection.
Article in Journal of virology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 49 citations in OpenAlex.
- A review on current status of antiviral siRNA.Reviews in medical virology · 2018Review
- The DNA damage response promotes polyomavirus JC infection by nucleus to cytoplasm NF- kappaB activation.Virology journal · 2017Article
- Gene Editing Approaches against Viral Infections and Strategy to Prevent Occurrence of Viral Escape.PLoS pathogens · 2016Review
- Emerging From the Unknown: Structural and Functional Features of Agnoprotein of Polyomaviruses.Journal of cellular physiology · 2016Review
- The Brd4 acetyllysine-binding protein is involved in activation of polyomavirus JC.Journal of neurovirology · 2016Article
- Expression of Signaling Molecules in Progressive Multifocal Leukoencephalopathy.Current HIV research · 2016Article
- Article
- Polyomavirus JC infection inhibits differentiation of oligodendrocyte progenitor cells.Journal of neuroscience research · 2013Article
- Progressive multifocal leukoencephalopathy: clinical and molecular aspects.Reviews in medical virology · 2012Review
- Role for tumor necrosis factor-α in JC virus reactivation and progressive multifocal leukoencephalopathy.Journal of neuroimmunology · 2011Article
- Efficient gene transfer using the human JC virus-like particle that inhibits human colon adenocarcinoma growth in a nude mouse model.Gene therapy · 2010Article
- Regulation of gene expression in primate polyomaviruses.Journal of virology · 2009Review
- Evidence for modulation of BAG3 by polyomavirus JC early protein.The Journal of general virology · 2009Article
- Update on PML: lessons from the HIV uninfected and new insights in pathogenesis and treatment.Current HIV/AIDS reports · 2008Review
- Article
- Broad-spectrum antiviral activity of small interfering RNA targeting the conserved RNA termini of Lassa virus.Antimicrobial agents and chemotherapy · 2007Article
- Natalizumab and progressive multifocal leucoencephalopathy.Annals of the rheumatic diseases · 2006Review
- Cross-interaction between JC virus agnoprotein and human immunodeficiency virus type 1 (HIV-1) Tat modulates transcription of the HIV-1 long terminal repeat in glial cells.Journal of virology · 2006Article
- Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy.Journal of virology · 2006Article
- Phosphorylation mutants of JC virus agnoprotein are unable to sustain the viral infection cycle.Journal of virology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human polyomavirus, JC virus (JCV), encodes two regulatory proteins at the early (T antigen) and the late (agnoprotein) phases of viral infection whose activities are important for the production of the viral capsid proteins and the dysregulation of several host factors and their functions. For this study, we designed and utilized an RNA interference strategy via small interfering RNAs (siRNAs) that targeted the expression of T antigen and agnoprotein in human astrocytic cells. The treatment of cells with specific siRNA oligonucleotides targeting a conserved region of T antigen, nucleotides (nt) 4256 to 4276 (Mad-1 strain), caused a >50% decline in the level of T antigen and in its transcriptional activity upon the viral capsid genes as well as a significant reduction in viral DNA replication in infected cells. Similarly, a single siRNA that aimed at nt 324 to 342 of agnoprotein noticeably reduced early and late viral protein production. A combined treatment of the infected cells with both T-antigen and agnoprotein siRNAs completely abolished viral capsid protein production, indicative of the ability of the siRNAs to effectively halt multiplication of the virus in infected cells. These observations provide a new avenue for possible treatments of patients with the JCV-induced demyelinating disease progressive multifocal leukoencephalopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.